Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT02676843
• Date of registration: 15/01/2016
• Prospective Registration: Yes
• Primary sponsor: Columbia University
• Public title: Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
• Scientific title: Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
• Date of first enrolment: April 2016
• Target sample size: 7
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT02676843
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).
• Phase: Phase 2

Countries of recruitment

United States

Contacts

• Name: Edward Huey, MD
• Affiliation: Columbia University

Key inclusion & exclusion criteria

Inclusion Criteria:

- Members of families with established MAPT mutations, who either have the capacity to
consent to participate in the protocol, or else have designated a surrogate/proxy to
consent to participate in this study

Exclusion Criteria:

- Unwillingness to participate

- Usage of medication which significantly prolongs QT interval

- Pregnancy or plans for pregnancy within 90 days after participating in study



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Frontotemporal Dementia (FTD)

Tauopathies

Frontotemporal Lobar Degeneration (FTLD)

Intervention(s)

Drug: 18F-AV-1451

Primary Outcome(s)

SUVR of 18F-AV-1451 [Time Frame: Baseline, 12-month follow up]

Secondary ID(s)

R01NS076837

AAAP4551

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

National Institute of Neurological Disorders and Stroke (NINDS)

Results

• Results available: Yes
• Date Posted: 06/12/2019
• URL: https://clinicaltrials.gov/ct2/show/results/NCT02676843